C - Chemistry – Metallurgy – 07 – D
Patent
C - Chemistry, Metallurgy
07
D
C07D 413/06 (2006.01) A61K 31/4184 (2006.01) A61K 31/4439 (2006.01) A61K 31/5377 (2006.01) A61P 35/00 (2006.01) C07D 235/06 (2006.01) C07D 235/14 (2006.01) C07D 401/06 (2006.01) C07D 403/06 (2006.01)
Patent
CA 2478534
Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts and prodrugs thereof, wherein W, t, R1, R2, R7, R9, R10, R11 and R12 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals. Also disclosed is a method of using such compounds in the treatment of hyperproliferative diseases in mammals, and pharmaceutical compositions containing such compounds.
La présente invention concerne des composés de formule (I), dans laquelle W, t, R?1¿, R?2¿, R?7¿, R?9¿, R?10¿, R?11¿ et R?12¿ sont tels que définis dans la description, ainsi que des sels et des promédicaments de ceux-ci, acceptables d'un point de vue pharmaceutique. De tels composés sont des inhibiteurs de MEK et sont utilisés pour traiter des maladies hyperprolifératives, telles que le cancer et les inflammations, chez les mammifères. La présente invention concerne également un procédé d'utilisation de ces composés pour traiter des maladies hyperprolifératives chez les mammifères, ainsi que des compositions pharmaceutiques contenant ces composés.
Hurley T. Brian
Lyssikatos Joseph P.
Marlow Allison L.
Wallace Eli M.
Array Biopharma Inc.
Gowling Lafleur Henderson Llp
LandOfFree
N3 alkylated benzimidazole derivatives as mek inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with N3 alkylated benzimidazole derivatives as mek inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and N3 alkylated benzimidazole derivatives as mek inhibitors will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1917648